Dr. Reddy’s CEO Seeks To Acquire Global “String Of Pearls”
This article was originally published in PharmAsia News
Dr. Reddy's Laboratories CEO GV Prasad plans a "string of pearls," companies around the globe it can acquire to expand the firm's presence abroad. In doing so, Dr. Reddy's would leave major acquisitions to others and concentrate instead on branded drugs in the United States and generics and custom pharma services there and in other markets. The company expects the smaller acquisitions to pay off in the medium and long term. The plans are reflected in the company's announcement it would acquire BASF and its U.S. business for $40 million. (Click here for more
You may also be interested in...
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.